Systemic immunotherapy with micellar resiquimod-polymer conjugates triggers a robust antitumor response in a breast cancer model

Resiquimod is an immunopotent toll-like receptor 7/8 agonist with anti-tumor activity. Despite being potent against skin cancers, it’s poorly tolerated systemically due to toxicity. Integrating resiquimod into nanoparticles presents an avenue to circumvent the toxicity problem. Herein, the preparati...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Adv Healthc Mater
Main Authors: Kakwere, Hamilton, Zhang, Hua, Ingham, Elizabeth S., Nura-Raie, Marina, Tumbale, Spencer K., Allen, Riley, Tam, Sarah M., Wu, Bo, Liu, Cheng, Kheirolomoom, Azadeh, Fite, Brett Z., Ilovitsh, Asaf, Lewis, Jamal S., Ferrara, Katherine W.
Formato: Artigo
Idioma:Inglês
Publicado em: 2021
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8153207/
https://ncbi.nlm.nih.gov/pubmed/33646600
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/adhm.202100008
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados